Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Geographic Atrophy Secondary to Age-related Macular Degeneration Clear all
Terminated No phase listed Observational
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration, Geographic Atrophy, Macular Atrophy
Interventions
Not listed
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced May 22, 2026, 5:16 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
CTx001
Genetic
Lead sponsor
Complement Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Carmel, Indiana • Reno, Nevada • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 22, 2026, 5:16 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Complement Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Mountain View, California • Carmel, Indiana • Reno, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 22, 2026, 5:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Geographic Atrophy, Dry Age-Related Macular Degeneration
Interventions
Avacincaptad Pegol, Sham
Drug · Other
Lead sponsor
IVERIC bio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced May 22, 2026, 5:16 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 22, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
GT005
Drug
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 22, 2026, 5:16 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Geographic Atrophy
Interventions
NGM621
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Arcadia, California • Newport Beach, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced May 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Geographic Atrophy
Interventions
JNJ-81201887, Prednisone, Placebo, Triamcinolone, Sham Procedure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 22, 2026, 5:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Geographic Atrophy
Interventions
OCU410
Genetic
Lead sponsor
Ocugen
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 22, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Age-Related Maculopathy
Interventions
RN6G, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
83
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced May 22, 2026, 5:16 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Macular Degeneration, Age-related, Geographic Atrophy
Interventions
BI 771716, Pegcetacoplan, Sham comparator to BI 771716
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
APL-2, Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Bakersfield, California • Oxnard, California • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced May 22, 2026, 5:16 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
FWY003, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Huntington Beach, California • Sacramento, California • Boynton Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 5:16 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Lampalizumab, Sham
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
76
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced May 22, 2026, 5:16 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
i-Lumen AMD
Device
Lead sponsor
i-Lumen Scientific AUS PTY LTD
Industry
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Manchester, Connecticut • Lemont, Illinois • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 22, 2026, 5:16 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Geographic Atrophy
Interventions
No intervention
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Springdale, Arkansas • Campbell, California • Glendale, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced May 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
Avacincaptad Pegol, Sham
Drug
Lead sponsor
IVERIC bio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
96
States / cities
Beverly Hills, California • Campbell, California • Fresno, California + 86 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced May 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced May 22, 2026, 5:16 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Geographic Atrophy of the Macula
Interventions
GAL-101, Placebo
Drug
Lead sponsor
Galimedix Therapeutics Inc
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 22, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced May 22, 2026, 5:16 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Geographic Atrophy
Interventions
No intervention
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Pensacola, Florida • Chesterfield, Missouri • Charlotte, North Carolina + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced May 22, 2026, 5:16 AM EDT
Completed Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ORACEA®, Placebo
Drug
Lead sponsor
Paul Yates, MD, PhD
Other
Eligibility
55 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
37
States / cities
Glendale, California • Poway, California • Golden, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced May 22, 2026, 5:16 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Geographic Atrophy of the Macula, Macular Degeneration
Interventions
AVD-104, Avacincaptad
Drug
Lead sponsor
Aviceda Therapeutics, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
56
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 22, 2026, 5:16 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Lampalizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
122
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced May 22, 2026, 5:16 AM EDT